Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Dec 18:10:1295274.
doi: 10.3389/fcvm.2023.1295274. eCollection 2023.

Commentary: The safety and efficacy of balloon-expandable vs. self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis

Affiliations
Comment

Commentary: The safety and efficacy of balloon-expandable vs. self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis

Michael J Reardon et al. Front Cardiovasc Med. .
No abstract available

Keywords: TAVI; TAVR; aortic stenosis; balloon-expandable; randomized controlled trial; self-expanding.

PubMed Disclaimer

Conflict of interest statement

MR reports receiving personal consulting fees from Abbott, Boston Scientific, Gore Medical and Medtronic outside of the submitted work. TB serves as a proctor for Medtronic and reports receiving personal consulting fees from Medtronic outside the submitted work. JP is an employee and shareholder of Medtronic.

Figures

Figure 1
Figure 1
Randomized controlled trials comparing TAVR with surgery. (A) Primary endpoint of the PARTNER 1 A randomized controlled trial in high surgical risk patients. (B) Primary endpoint of the CoreValve high risk randomized controlled trial in high surgical risk patients. (C) Rates of structural valve deterioration in patients treated with CoreValve/Evolut TAVR or surgery. Reproduced with permission from O'Hair D, Yakubov SJ, Grubb KJ, Oh JK, Ito S, Deeb GM, et al. Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation in Patients at Intermediate or High Risk. JAMA Cardiol. 2022. Copyright© 2022 American Medical Association. All rights reserved. (D) Three Year primary endpoint in the Evolut low risk randomized controlled trial. Reprinted from Forrest JK, Deeb GM, Yakubov SJ, Gada H, Mumtaz MA, Ramlawi B, et al. 3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. J Am Coll Cardiol. 2023;81(17):1663–74, with permission from Elsevier.

Comment on

References

    1. Senguttuvan NB, Bhatt H, Balakrishnan VK, Krishnamoorthy P, Goel S, Reddy PMK, et al. The safety and efficacy of balloon-expandable versus self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis. Front Cardiovasc Med. (2023) 10:1130354. 10.3389/fcvm.2023.1130354 - DOI - PMC - PubMed
    1. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. (2011) 364(23):2187–98. 10.1056/NEJMoa1103510 - DOI - PubMed
    1. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. (2014) 370(19):1790–8. 10.1056/NEJMoa1400590 - DOI - PubMed
    1. Pibarot P, Ternacle J, Jaber WA, Salaun E, Dahou A, Asch FM, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 trial. J Am Coll Cardiol. (2020) 76(16):1830–43. 10.1016/j.jacc.2020.08.049 - DOI - PubMed
    1. O'Hair D, Yakubov SJ, Grubb KJ, Oh JK, Ito S, Deeb GM, et al. Structural valve deterioration after self-expanding transcatheter or surgical aortic valve implantation in patients at intermediate or high risk. JAMA Cardiol. (2022) 8(2):111–9. 10.1001/jamacardio.2022.4627 - DOI - PMC - PubMed

LinkOut - more resources